{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-188090","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2023-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.385876+00:00","generated_at":"2026-06-13T07:30:48.324297+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MEI Pharma urges shareholders to vote FOR Infinity merger ahead of July 23 special meeting","bullets":["MEI mailed letter to shareholders on July 17, 2023, pleading vote FOR the Infinity (INFI) merger at the July 23 special meeting.","Combined company would hold three clinical-stage assets: Eganelisib, Voruciclib, ME-344 with data catalysts in 6-24 months.","ISS and Glass Lewis both recommend FOR; ISS reiterated its support as recently as July 14, 2023.","MEI claims the deal creates a well-capitalized pipeline and leverages the clinical expertise of both teams."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-188090","json":"https://secwatch.observer/filing/0001193125-23-188090.json","markdown":"https://secwatch.observer/filing/0001193125-23-188090.md","text":"https://secwatch.observer/filing/0001193125-23-188090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523188090/0001193125-23-188090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523188090/d536977d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:30:48.324297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}